

Helen Gogas

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/2610500/publications.pdf](https://exaly.com/author-pdf/2610500/publications.pdf)

Version: 2024-02-01

127
papers

13,094
citations

173697

29
h-index

24438

110
g-index

129
all docs

129
docs citations

129
times ranked

17007
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation. <i>New England Journal of Medicine</i> , 2015, 372, 320-330.	27.3	4,795
2	Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1877-1888.	27.3	1,572
3	Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. <i>Lancet, The</i> , 2015, 386, 444-451.	14.0	1,175
4	Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 626-636.	27.3	909
5	Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. <i>Nature Medicine</i> , 2019, 25, 1916-1927.	30.9	541
6	Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2020, 395, 1835-1844.	14.0	423
7	Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology, The</i> , 2020, 21, 1465-1477.	10.9	330
8	Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy. <i>JAMA Oncology</i> , 2019, 5, 187.	7.2	295
9	Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. <i>European Journal of Cancer</i> , 2015, 51, 2792-2799.	2.9	269
10	Acquired IFN γ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. <i>Nature Communications</i> , 2017, 8, 15440.	13.1	195
11	Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. <i>European Journal of Cancer</i> , 2017, 82, 45-55.	2.9	160
12	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. <i>Nature Genetics</i> , 2020, 52, 494-504.	21.7	138
13	Mucosal melanoma of the head and neck. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 112, 136-152.	4.5	125
14	Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 3937-3946.	1.7	119
15	Toxicity management of immunotherapy for patients with metastatic melanoma. <i>Annals of Translational Medicine</i> , 2016, 4, 272-272.	1.7	92
16	Randomized Phase III Trial Evaluating Spaltalizumab Plus Dabrafenib and Trametinib for <i>BRAF</i> V600 Mutant Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 1428-1438.	1.7	90
17	Reactivation of tuberculosis in cancer patients following administration of immune checkpoint inhibitors: current evidence and clinical practice recommendations. , 2019, 7, 239.		81
18	Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells. <i>Journal of Clinical Investigation</i> , 2018, 128, 3840-3852.	8.4	79

#	ARTICLE	IF	CITATIONS
19	Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. <i>European Journal of Cancer</i> , 2015, 51, 833-840.	2.9	71
20	Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy. <i>Cancer Investigation</i> , 2017, 35, 443-455.	1.4	67
21	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 119, 168-178.	2.9	61
22	Survivin beyond physiology: Orchestration of multistep carcinogenesis and therapeutic potentials. <i>Cancer Letters</i> , 2014, 347, 175-182.	7.3	57
23	Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. <i>Oncotarget</i> , 2016, 7, 5074-5087.	1.9	54
24	Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9502-9502.	1.7	52
25	Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 609-619.	2.5	48
26	Immunotherapy for advanced melanoma: Fulfilling the promise. <i>Cancer Treatment Reviews</i> , 2013, 39, 879-885.	7.8	44
27	Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. <i>Cancer</i> , 2010, 116, 4326-4333.	4.2	35
28	First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 765-772.	4.3	35
29	Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047). <i>Journal of Clinical Oncology</i> , 2022, 40, 360385-360385.	1.7	33
30	Talimogene laherparepvec upregulates immune-cell populations in non-injected lesions: findings from a phase II, multicenter, open-label study in patients with stage III/IV melanoma. , 2021, 9, e001621.		32
31	Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma. <i>Cancer Medicine</i> , 2019, 8, 6585-6594.	2.9	31
32	TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting. <i>Oncotarget</i> , 2016, 7, 32731-32753.	1.9	30
33	IFN- γ Cancer Immunotherapy: New Kid on the Block. <i>Immunotherapy</i> , 2016, 8, 877-888.	2.0	30
34	Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers. <i>Cancer Genomics and Proteomics</i> , 2017, 14, 181-195.	2.0	30
35	Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study. <i>PLoS ONE</i> , 2015, 10, e0140293.	2.5	29
36	The Role of CXCL13 and CXCL9 in Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, e36-e53.	2.5	29

#	ARTICLE	IF	CITATIONS
37	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 121, 144-153.	2.9	27
38	Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 173, 103663.	4.5	27
39	When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report. , 2020, 8, e001322.		26
40	The role of taxanes in the treatment of metastatic melanoma. <i>Melanoma Research</i> , 2004, 14, 415-420.	1.2	25
41	Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial. <i>Journal of Translational Medicine</i> , 2010, 8, 108.	4.4	25
42	MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer. <i>Journal of Translational Medicine</i> , 2016, 14, 136.	4.4	25
43	Prediction of Melanoma Risk in a Southern European Population Based on a Weighted Genetic Risk Score. <i>Journal of Investigative Dermatology</i> , 2016, 136, 690-695.	0.7	25
44	Incomplete Vogtâ€“Koyanagiâ€“Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma. <i>Melanoma Research</i> , 2018, 28, 648-651.	1.2	23
45	Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy. , 2020, 8, e000943.		23
46	Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in <i>BRAF</i>-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9504-9504.	1.7	23
47	Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond. <i>Vaccines</i> , 2021, 9, 1111.	4.5	22
48	Associations of angiogenesis-related proteins with specific prognostic factors, breast cancer subtypes and survival outcome in early-stage breast cancer patients. A Hellenic Cooperative Oncology Group (HeCOG) trial. <i>PLoS ONE</i> , 2018, 13, e0200302.	2.5	21
49	Bullous Pemphigoidâ€“like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature. <i>Journal of Immunotherapy</i> , 2018, 41, 164-167.	2.5	20
50	Adverse events 2.0â€“Let us get SERIOs. <i>European Journal of Cancer</i> , 2019, 112, 29-31.	2.9	19
51	Prognostic impact of stromal and intratumoral CD3, CD8 and FOXP3 in adjuvantly treated breast cancer: do they add information over stromal tumor-infiltrating lymphocyte density?. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1549-1564.	4.3	19
52	Regulatory T-cell Transcriptomic Reprogramming Characterizes Adverse Events by Checkpoint Inhibitors in Solid Tumors. <i>Cancer Immunology Research</i> , 2021, 9, 726-734.	3.4	19
53	Detection of circulating tumor cells in colorectal and gastric cancer using a multiplex PCR assay. <i>Anticancer Research</i> , 2014, 34, 3083-92.	1.1	19
54	Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 301-314.	6.8	18

#	ARTICLE	IF	CITATIONS
55	Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer: A Phase II Trial of the Hellenic Cooperative Oncology Group. <i>Clinical Breast Cancer</i> , 2010, 10, 230-237.	2.5	17
56	Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2016, 16, 291-298.e3.	2.5	17
57	Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. <i>Translational Oncology</i> , 2017, 10, 589-598.	3.7	17
58	Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event management algorithm in patients treated with adjuvant dabrafenib plus trametinib: Primary results of COMBI-APlus. <i>European Journal of Cancer</i> , 2022, 163, 79-87.	2.9	17
59	Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 307-321.	2.5	16
60	Real-world safety and efficacy data of immunotherapy in patients with cancer and autoimmune disease: the experience of the Hellenic Cooperative Oncology Group. <i>Cancer Immunology, Immunotherapy</i> , 2021, , 1.	4.3	16
61	Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year—a Hellenic Cooperative Oncology Group study. <i>Anticancer Research</i> , 2004, 24, 1947-52.	1.1	16
62	Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study. <i>Journal of Translational Medicine</i> , 2015, 13, 171.	4.4	15
63	An overview of antibody–drug conjugates in oncological practice. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096299.	3.2	15
64	Differential Expression of the Insulin-Like Growth Factor Receptor among Early Breast Cancer Subtypes. <i>PLoS ONE</i> , 2014, 9, e91407.	2.5	15
65	Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. <i>Journal of Translational Medicine</i> , 2017, 15, 30.	4.4	14
66	Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with <i>BRAF</i> V600-mutant melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10012-10012.	1.7	14
67	alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies. <i>BMC Clinical Pathology</i> , 2014, 14, 28.	1.8	13
68	Prognostic Significance of IGF-1 Signalling Pathway in Patients With Advanced Non-small Cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 4185-4190.	1.1	13
69	Opposite Prognostic Impact of Single PTEN-loss and <i>PIK3CA</i> Mutations in Early High-risk Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2019, 16, 195-206.	2.0	13
70	Hypercalcemia of malignancy treated with cinacalcet. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2017, 2017, .	0.5	13
71	Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy. <i>Cancer Medicine</i> , 2018, 7, 5066-5082.	2.9	12
72	Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival. , 2021, 9, e003188.		12

#	ARTICLE	IF	CITATIONS
73	A Practical Guide for the Follow-Up of Patients with Advanced Basal Cell Carcinoma During Treatment with Hedgehog Pathway Inhibitors. <i>Oncologist</i> , 2019, 24, e755-e764.	3.8	11
74	Application of the International System for Reporting Serous Fluid Cytopathology with Cytohistological Correlation and Risk of Malignancy Assessment. <i>Diagnostics</i> , 2021, 11, 2223.	2.7	11
75	Vinorelbine in Combination with Interleukin-2 as Second-Line Treatment in Patients with Metastatic Melanoma. A Phase II Study of the Hellenic Cooperative Oncology Group. <i>Cancer Investigation</i> , 2004, 22, 832-839.	1.4	10
76	Expanded access programmes: patient interests versus clinical trial integrity. <i>Lancet Oncology</i> , The, 2015, 16, 15-17.	10.9	10
77	Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection. <i>Vaccines</i> , 2021, 9, 1017.	4.5	10
78	Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2017, 37, 2334.	1.1	10
79	The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy. <i>Anticancer Research</i> , 2017, 37, 2947-2957.	1.1	9
80	The diagnosis and management of sarcoid-like reactions in patients with melanoma treated with BRAF and MEK inhibitors. A case series and review of the literature. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110473.	3.2	9
81	Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes. <i>PLoS ONE</i> , 2016, 11, e0163138.	2.5	8
82	Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials. <i>Clinical Breast Cancer</i> , 2018, 18, 53-62.e3.	2.5	8
83	Predictive biomarkers to chemotherapy in patients with advanced melanoma receiving the combination of cisplatin–vinblastine–temozolomide (PVT) as first-line treatment: a study of the Hellenic Cooperative Oncology Group (HECOG). <i>Anticancer Research</i> , 2015, 35, 1105-13.	1.1	8
84	Prognostic Significance of VEGFC and VEGFR1 mRNA Expression According to HER2 Status in Breast Cancer: A Study of Primary Tumors from Patients with High-risk Early Breast Cancer Participating in a Randomized Hellenic Cooperative Oncology Group Trial. <i>Anticancer Research</i> , 2015, 35, 4023-36.	1.1	8
85	Phase II study SECOMBIT (sequential combo immuno and target therapy study): A subgroup analysis with a longer follow-up.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9535-9535.	1.7	8
86	Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9505-9505.	1.7	8
87	Prognosis and Management of <i>BRAF</i> V600E-Mutated Pregnancy-Associated Melanoma. <i>Oncologist</i> , 2020, 25, e1209-e1220.	3.8	7
88	A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III). <i>Cancers</i> , 2021, 13, 2466.	3.8	7
89	Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review. <i>BMC Gastroenterology</i> , 2021, 21, 227.	2.0	7
90	Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). <i>European Journal of Cancer</i> , 2021, 152, 116-128.	2.9	7

#	ARTICLE	IF	CITATIONS
91	Epidemiological trends in the diagnosis of melanoma in a Southern European population: analysis of a large database from a tertiary referral center. <i>Melanoma Research</i> , 2018, 28, 348-358.	1.2	6
92	Identifying the optimum first-line therapy in BRAF-mutant metastatic melanoma. <i>Expert Review of Anticancer Therapy</i> , 2020, 20, 53-62.	2.4	6
93	An analysis of nivolumab-mediated adverse events and association with clinical efficacy in resected stage III or IV melanoma (CheckMate 238).. <i>Journal of Clinical Oncology</i> , 2019, 37, 9584-9584.	1.7	6
94	Interaction Between Beta-Catenin and EGFR Expression by Immunohistochemistry Identifies Prognostic Subgroups in Early High-risk Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2016, 36, 2365-78.	1.1	6
95	Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAF ^{V600} -positive melanoma: Interim analysis of the ImmunoCobiVem study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9548-9548.	1.7	6
96	Emergency Surgery for Metastatic Melanoma. <i>International Journal of Surgical Oncology</i> , 2014, 2014, 1-4.	0.6	5
97	Overall survival (OS) with first-line atezolizumab (A) or placebo (P) in combination with vemurafenib (V) and cobimetinib (C) in BRAF ^{V600} mutation-positive advanced melanoma: Second interim OS analysis of the phase 3 IMspire150 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9547-9547.	1.7	5
98	EMRseq: Registry-based outcome analysis on 1,000 patients with BRAF V600 mutated metastatic melanoma in Europe treated with either immune checkpoint or BRAF/MEK inhibition.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9540-9540.	1.7	5
99	Lymphocyte Subpopulations and Interleukin Levels in High-Risk Melanoma Patients Treated With High-Dose Interferon A-2B. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 591-596.	1.4	4
100	Abdominal Emergencies in Patients with Stage IV Melanoma: The Role of Surgery: A Single-centre Experience. <i>Anticancer Research</i> , 2018, 38, 3713-3718.	1.1	4
101	A life-threatening drug-drug interaction between capecitabine and brivudine in a patient with metastatic breast cancer. <i>Journal of Chemotherapy</i> , 2019, 31, 424-427.	1.5	4
102	Androgen Receptor and PIM1 Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 147-156.	2.0	4
103	Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study. <i>PLoS ONE</i> , 2016, 11, e0164013.	2.5	4
104	The fate of BRCA1-related germline mutations in triple-negative breast tumors. <i>American Journal of Cancer Research</i> , 2017, 7, 98-114.	1.4	4
105	Primary analysis of a phase 2, open-label, multicenter trial of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) for the treatment (Tx) of patients (pts) with advanced melanoma (MEL) who progressed on prior anti-PD-1 therapy: MASTERKEY-115.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9518-9518.	1.7	4
106	Adjusting Breast Cancer Patient Prognosis with Non-HER2-Gene Patterns on Chromosome 17. <i>PLoS ONE</i> , 2014, 9, e103707.	2.5	3
107	Extending the conversation over the immune-related hepatotoxicity: author response to Dr. Gauci et al., 2021, 9, e002391.		3
108	Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 102-102.	1.7	3

#	ARTICLE	IF	CITATIONS
109	A New Mathematical Model for the Interpretation of Translational Research Evaluating Six CTLA-4 Polymorphisms in High-Risk Melanoma Patients Receiving Adjuvant Interferon. PLoS ONE, 2014, 9, e86375.	2.5	3
110	Multichamber Involvement of Metastatic Cardiac Melanoma. Diagnostics, 2022, 12, 587.	2.7	3
111	Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer. Cancer Genomics and Proteomics, 2020, 17, 181-193.	2.0	2
112	Neuromuscular Complications of Targeted Anticancer Agents: Can Tyrosine Kinase Inhibitors Induce Myasthenia Gravis? Getting Answers From a Case Report up to a Systematic Review. Frontiers in Oncology, 2021, 11, 727010.	2.9	2
113	Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 Trial. British Journal of Cancer, 2022, 127, 695-703.	6.5	2
114	Abstract CT557: Phase 1/2 study of quavonlimab (Qmab) + pembrolizumab (pembro) in patients (pts) with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor. Cancer Research, 2022, 82, CT557-CT557.	0.9	2
115	Dabrafenib (D) and trametinib (T) plus spartalizumab (S) in patients (pts) with previously untreated <i>BRAF</i> V600 mutant unresectable or metastatic melanoma: Three-year overall survival (OS) data from the randomized part 3 of the phase III COMBI-i trial.. Journal of Clinical Oncology, 2022, 40, 9527-9527.	1.7	2
116	Clinical considerations about the coexistence of melanoma and chronic lymphocytic leukemia in the era of targeted therapies, triggered by rare clinical scenarios. A case series and review of the literature. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592096236.	3.2	1
117	A case report of immune-mediated arthritis in a patient with cutaneous melanoma receiving checkpoint inhibition therapy. Medicine (United States), 2020, 99, e19439.	1.1	1
118	Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. Oncotarget, 2020, 11, 1-14.	1.9	1
119	Beyond Immunotherapy: Seizing the Momentum of Oncolytic Viruses in the Ideal Platform of Skin Cancers. Cancers, 2022, 14, 2873.	3.8	1
120	Reply to S.S. Agarwala et al. Journal of Clinical Oncology, 2009, 27, e84-e84.	1.7	0
121	Reply to P. Mohr et al. Journal of Clinical Oncology, 2009, 27, e71-e71.	1.7	0
122	Prognostic significance of distant metastasis-free interval in patients with relapsed melanoma treated with BRAF with or without MEK inhibitors. Melanoma Research, 2019, 29, 428-434.	1.2	0
123	New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma. Melanoma Research, 2020, 30, 206-208.	1.2	0
124	Atezolizumab plus vemurafenib and cobimetinib for the treatment of BRAF V600-mutant advanced melanoma: from an hypothetic triplet to an approved regimen. Expert Review of Precision Medicine and Drug Development, 2021, 6, 349-360.	0.7	0
125	Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.. Journal of Clinical Oncology, 2018, 36, e18609-e18609.	1.7	0
126	The diagnosis and management of sarcoid-like reactions in patients with melanoma treated with BRAF and MEK inhibitors. A case series and review of the literature. Therapeutic Advances in Medical Oncology, 2021, 13, 17588359211047349.	3.2	0

#	ARTICLE	IF	CITATIONS
127	301 Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study. , 2020, , .		0